|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PHLDB2 |
Gene summary for PHLDB2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PHLDB2 | Gene ID | 90102 |
| Gene name | pleckstrin homology like domain family B member 2 | |
| Gene Alias | LL5b | |
| Cytomap | 3q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q86SQ0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 90102 | PHLDB2 | CCI_1 | Human | Cervix | CC | 1.53e-03 | 9.03e-01 | 0.528 |
| 90102 | PHLDB2 | CCI_3 | Human | Cervix | CC | 7.19e-05 | 6.17e-01 | 0.516 |
| 90102 | PHLDB2 | CCII_1 | Human | Cervix | CC | 7.87e-06 | 3.42e-01 | 0.3249 |
| 90102 | PHLDB2 | sample1 | Human | Cervix | CC | 3.20e-22 | 8.14e-01 | 0.0959 |
| 90102 | PHLDB2 | T1 | Human | Cervix | CC | 6.64e-45 | 9.32e-01 | 0.0918 |
| 90102 | PHLDB2 | LZE4T | Human | Esophagus | ESCC | 1.39e-33 | 1.16e+00 | 0.0811 |
| 90102 | PHLDB2 | LZE7T | Human | Esophagus | ESCC | 6.41e-08 | 1.60e+00 | 0.0667 |
| 90102 | PHLDB2 | LZE8T | Human | Esophagus | ESCC | 3.86e-08 | 3.59e-01 | 0.067 |
| 90102 | PHLDB2 | LZE20T | Human | Esophagus | ESCC | 4.68e-02 | 1.11e-01 | 0.0662 |
| 90102 | PHLDB2 | LZE21T | Human | Esophagus | ESCC | 5.44e-07 | 3.37e-01 | 0.0655 |
| 90102 | PHLDB2 | P2T-E | Human | Esophagus | ESCC | 5.40e-04 | -1.07e-01 | 0.1177 |
| 90102 | PHLDB2 | P4T-E | Human | Esophagus | ESCC | 1.44e-16 | 7.51e-01 | 0.1323 |
| 90102 | PHLDB2 | P5T-E | Human | Esophagus | ESCC | 1.71e-14 | 5.23e-01 | 0.1327 |
| 90102 | PHLDB2 | P9T-E | Human | Esophagus | ESCC | 2.88e-34 | 1.29e+00 | 0.1131 |
| 90102 | PHLDB2 | P10T-E | Human | Esophagus | ESCC | 3.36e-07 | 2.54e-01 | 0.116 |
| 90102 | PHLDB2 | P11T-E | Human | Esophagus | ESCC | 1.31e-24 | 1.24e+00 | 0.1426 |
| 90102 | PHLDB2 | P12T-E | Human | Esophagus | ESCC | 3.70e-04 | 2.27e-01 | 0.1122 |
| 90102 | PHLDB2 | P15T-E | Human | Esophagus | ESCC | 2.04e-23 | 6.81e-01 | 0.1149 |
| 90102 | PHLDB2 | P16T-E | Human | Esophagus | ESCC | 3.44e-09 | 5.54e-02 | 0.1153 |
| 90102 | PHLDB2 | P17T-E | Human | Esophagus | ESCC | 2.22e-06 | 4.54e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:011002025 | Esophagus | ESCC | regulation of actomyosin structure organization | 59/8552 | 100/18723 | 4.98e-03 | 1.91e-02 | 59 |
| GO:19012033 | Esophagus | ESCC | positive regulation of extracellular matrix assembly | 9/8552 | 10/18723 | 5.09e-03 | 1.92e-02 | 9 |
| GO:190303420 | Esophagus | ESCC | regulation of response to wounding | 93/8552 | 167/18723 | 5.77e-03 | 2.14e-02 | 93 |
| GO:00850292 | Esophagus | ESCC | extracellular matrix assembly | 29/8552 | 45/18723 | 8.63e-03 | 3.04e-02 | 29 |
| GO:00353132 | Esophagus | ESCC | wound healing, spreading of epidermal cells | 14/8552 | 19/18723 | 1.27e-02 | 4.21e-02 | 14 |
| GO:19030532 | Esophagus | ESCC | regulation of extracellular matrix organization | 30/8552 | 48/18723 | 1.40e-02 | 4.57e-02 | 30 |
| GO:190188810 | Esophagus | ESCC | regulation of cell junction assembly | 109/8552 | 204/18723 | 1.53e-02 | 4.96e-02 | 109 |
| GO:00070447 | Lung | IAC | cell-substrate junction assembly | 36/2061 | 95/18723 | 6.81e-12 | 4.27e-09 | 36 |
| GO:00071607 | Lung | IAC | cell-matrix adhesion | 63/2061 | 233/18723 | 7.08e-12 | 4.27e-09 | 63 |
| GO:00315897 | Lung | IAC | cell-substrate adhesion | 85/2061 | 363/18723 | 8.57e-12 | 4.27e-09 | 85 |
| GO:00480416 | Lung | IAC | focal adhesion assembly | 34/2061 | 87/18723 | 9.46e-12 | 4.27e-09 | 34 |
| GO:00518937 | Lung | IAC | regulation of focal adhesion assembly | 29/2061 | 66/18723 | 1.01e-11 | 4.27e-09 | 29 |
| GO:00901097 | Lung | IAC | regulation of cell-substrate junction assembly | 29/2061 | 66/18723 | 1.01e-11 | 4.27e-09 | 29 |
| GO:01501157 | Lung | IAC | cell-substrate junction organization | 36/2061 | 101/18723 | 5.37e-11 | 1.52e-08 | 36 |
| GO:01501167 | Lung | IAC | regulation of cell-substrate junction organization | 29/2061 | 71/18723 | 8.86e-11 | 2.29e-08 | 29 |
| GO:00019527 | Lung | IAC | regulation of cell-matrix adhesion | 40/2061 | 128/18723 | 4.69e-10 | 9.93e-08 | 40 |
| GO:00108108 | Lung | IAC | regulation of cell-substrate adhesion | 57/2061 | 221/18723 | 5.09e-10 | 1.04e-07 | 57 |
| GO:00070158 | Lung | IAC | actin filament organization | 92/2061 | 442/18723 | 1.01e-09 | 1.93e-07 | 92 |
| GO:00343297 | Lung | IAC | cell junction assembly | 86/2061 | 420/18723 | 7.98e-09 | 1.10e-06 | 86 |
| GO:00510178 | Lung | IAC | actin filament bundle assembly | 40/2061 | 157/18723 | 2.66e-07 | 2.14e-05 | 40 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PHLDB2 | SNV | Missense_Mutation | novel | c.1172N>T | p.Asp391Val | p.D391V | Q86SQ0 | protein_coding | deleterious(0) | benign(0.203) | TCGA-A7-A425-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | adriamycin | PD |
| PHLDB2 | SNV | Missense_Mutation | novel | c.3502N>A | p.Asp1168Asn | p.D1168N | Q86SQ0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PHLDB2 | SNV | Missense_Mutation | c.359N>A | p.Gly120Glu | p.G120E | Q86SQ0 | protein_coding | tolerated_low_confidence(0.09) | benign(0.018) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| PHLDB2 | SNV | Missense_Mutation | c.1708N>G | p.Ile570Val | p.I570V | Q86SQ0 | protein_coding | tolerated(0.1) | benign(0.255) | TCGA-B6-A0WV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PHLDB2 | SNV | Missense_Mutation | c.604C>T | p.Pro202Ser | p.P202S | Q86SQ0 | protein_coding | deleterious(0) | possibly_damaging(0.549) | TCGA-BH-A1FU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| PHLDB2 | SNV | Missense_Mutation | c.1690N>C | p.Glu564Gln | p.E564Q | Q86SQ0 | protein_coding | deleterious(0.05) | benign(0.388) | TCGA-BH-A209-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PHLDB2 | SNV | Missense_Mutation | c.1608N>T | p.Arg536Ser | p.R536S | Q86SQ0 | protein_coding | tolerated(0.07) | benign(0.057) | TCGA-D8-A1XG-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| PHLDB2 | SNV | Missense_Mutation | c.3134N>T | p.Ala1045Val | p.A1045V | Q86SQ0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| PHLDB2 | SNV | Missense_Mutation | novel | c.7N>A | p.Glu3Lys | p.E3K | Q86SQ0 | protein_coding | deleterious_low_confidence(0) | benign(0.214) | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| PHLDB2 | SNV | Missense_Mutation | novel | c.3132N>T | p.Gln1044His | p.Q1044H | Q86SQ0 | protein_coding | deleterious(0) | possibly_damaging(0.885) | TCGA-LQ-A4E4-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |